Low Endophthalmitis Rates After Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operation Room

Freiberg, Florentina Joyce; Brynskov, Troels; Munk, Marion R.; Sørensen, Torben Lykke; Wolf, Sebastian; Wirth, Magdalena A.; Becker, Matthias; Michels, Stephan

doi:10.1097/iae.0000000000001488

Cited by 38 publications

(40 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another retrospective analysis including 40,011 IVI performed in the OR reported an EO rate of 0.007% [72]. Freiberg et al [73] have recently reported the series of 134,701 IVI performed in an OR with laminar airflow, with a very low rate of EO of 0.0074% per injection.…”

Section: Peri- /Injection Management In Intravitreal Pharmacotherapymentioning

confidence: 99%

2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations

et al. 2018

View full text Add to dashboard Cite

Intravitreal injections (IVI) have become the most common intraocular procedure worldwide with increasing numbers every year. The article presents the most up-to-date review on IVI epidemiology and techniques. Unfortunately, important issues related to pre-, peri- and postinjection management lack randomized clinical trials for a final conclusion. Also, a great diversity of approaches exists worldwide. Therefore, expert consensus recommendations on IVI techniques are provided.

show abstract

Section: Peri- /Injection Management In Intravitreal Pharmacotherapymentioning

confidence: 99%

2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Regarding the safety profile, the incidence of endophthalmitis did not significantly differ from those reported in the literature [37][38][39][40][41] . Based on the currently available scientific evidence, intravitreal injections performed at the operating room did not have lower rates of endophthalmitis than those performed in the office [21][22][23][37][38][39][40][41] .…”

Section: Discussionmentioning

confidence: 60%

“…The incidence of endophthalmitis after intravitreal injections of anti-VEGF or corticosteroids is low [37][38][39][40][41] . In a Retrospective, nationwide multicenter case series conducted in France, which evaluated 316,576 intravitreal injections, the overall incidence of endophthalmitis was 0.021% (2.1 in 10,000 injections) (95% CI, 0.016%À0.026%) 37 .…”

Section: Discussionmentioning

confidence: 99%

Can the dexamethasone intravitreal implant Ozurdex be safely administered in an out-of-operating room setting?

Mdp

Armadá-Maresca

Amorena-Santesteban

et al. 2020

Journal of Drug Assessment

View full text Add to dashboard Cite

Purpose: To describe a standardized protocol of the dexamethasone intravitreal (DEX) implant Ozurdex (Allergan, Dublin, Ireland) performed in a controlled environment surgical cabin (CESC). Methods: Retrospective and observational study conducted on patients who underwent a DEX implant between May 2011 and June 2019, in a third level University Hospital. The controlled environment surgical cabin (ArcSterile, Imex, Valencia, Spain) used in this study was the MB 20 (2 m width, 1.60 m depth, and 2 m height) with an uninterrupted power system (ARSSAI1) to keep the cabin working for 20 min. The cabin was used in the open mode. A standardized protocol of intravitreal injections in controlled environment surgical cabin was designed. Results: From May 2011 to February 2015, a total of 454 DEX implants were performed in the operating room, whereas from March 2015 to June 2019, 1054 DEX devices were implanted using the CESC. The mean number of DEX implants/per week was significantly lower in the operating room than in the CESC [2.3 (2.1 to 2.5) versus 3.8 (3.6 to 4.1), mean difference 1.5 (1.2 to 1.8), p < 0.0001]. The incidence of endophthalmitis was similar in the two populations, 0/454 (0.0%; 95% CI 0.0 to 0.81%) and 0/1054 (0.0%; 95% CI 0.0 to 0.35%) in the operating room and in the CESC, respectively. Conclusions: The CESC may be a good alternative to the conventional operating room for the administration of the intravitreal DEX implant.

show abstract

“…28 El medio hospitalario hace necesario un comentario sobre las inyecciones intravítreas. 29 Entre 2003 y 2016 se realizaron 134.701 inyecciones intravítreas en quirófano bajo flujo laminar con máximas condiciones de esterilidad en el Hospital Universitario Zealand de Dinamarca y en el Hospital Triemli de Zurich y la Clinica Universitaria de Bern (Suiza). La tasa de endoftalmitis fue del 0.0074 %, con solo 4 casos con cultivo positivo: tres por Staphylococcus Epidermidis y un caso por Proteus spp.…”

Section: Uveítis Infecciosasunclassified

Lo mejor del año en uveítis 2017

Martínez-Rubio

Martínez-Lopez-Corell

Pascual-Camps

et al. 2018

Vis. Pan-Am.

View full text Add to dashboard Cite

show abstract

Low Endophthalmitis Rates After Intravitreal Anti-Vascular Endothelial Growth Factor Injections in an Operation Room

Abstract: The standardized sterile technique in an operation room with laminar airflow showed very low rates of endophthalmitis at three European sites.

Cited by 38 publications

References 20 publications

2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations

2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations

Can the dexamethasone intravitreal implant Ozurdex be safely administered in an out-of-operating room setting?

Lo mejor del año en uveítis 2017

Contact Info

Product

Resources

About